Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2017

01-07-2017 | Review Article

Retroperitoneal lymph node dissection: an update in testicular malignancies

Author: K. Yadav

Published in: Clinical and Translational Oncology | Issue 7/2017

Login to get access

Abstract

Management of testicular cancer has evolved through many breakthroughs. The decades of zeal to improve oncologic adequacy and to decrease morbidity has led to the current scientific knowledge of retroperitoneal lymph node dissection templates. Retroperitoneal lymph node dissection (RPLND) has potential for staging, prognostication and therapeutic importance in the management of testicular malignancy. RPLND has overcome limitations of current imaging which understage 30% of stage I disease and overstage 25–30% of stage II disease. For low-volume disease, RPLND is curative in up to 90% cases without adjuvant therapy and has important role in postchemotherapy residual disease. Risk of recurrence after RPLND is 1% and follow-up imaging can be limited, thus avoiding their potential risk of radiation exposure. RPLND reveals vital information of disease nature and guide adjuvant therapy. Despite the long evolution period, certain controversies still surround RPLND. We aim to refine this challenging management in the following manuscript based on available evidence.
Literature
1.
Skandalakis JE. Surgical anatomy: the embryologic and anatomic basis of modern surgery. Male genital system. chapter 25. New York: McGraw Hill; 2004.
2.
Most A. Uber die lymphgefässe und lymphdrüssendes hodens. Arch f Anat u Entweckingsgesh. 1899;113:387–93 (in German).
3.
Jamieson JK, Dobson JF. On the injection of lymphatics by prussian blue. J AnatPhysiol. 1910;45(Pt 1):7–10.
4.
Cuneo B. Note sur les lymphatiques du testicule. Bull Mem Soc Anat Paris. 1901;76:105 (in French).
5.
Chevassu M. Deuxcasd’epitheliome du testiculetraite par castration et l’ablation des ganglions lumboaortique. Bull MemSoc Chir Paris. 1910;36:236–62 (in French).
6.
Bland-Sutton J. An operation for lumbar gland removal in cases of testis tumour. Lancet. 1909;1:1406.
7.
Hinman F. The operative treatment of tumors of the testicle. JAMA. 1914;58:2009–15.CrossRef
8.
Patton JF, Hewitt CB, Mallis N. Diagnosis and treatment of tumors of the testis. J Am Med Assoc. 1959;171:2194–8.CrossRefPubMed
9.
Cooper J, Leadbetter W, Chute R. The thoracoabdominal approach for retroperitoneal gland dissection: its application to testis tumors. Surg Gynecol Obstet. 1950;90:486.
10.
Donohue JP. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am. 1977;4(3):509–21.PubMed
11.
Busch FM, Sayegh ES. Roentgenographic visualization of human testicular lymphatics: a preliminary report. J Urol. 1963;89:106–10.PubMed
12.
Ray B, Hajdu SI, Whitmore WF Jr. Proceedings: distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer. 1974;33(2):340–8.CrossRefPubMed
13.
Weisbach L, Boedefeld E. Localization of solitary and multiple metastasis in stage II non seminomatous testis tumors as a basis for a modified staging lymph node dissection in stage I. J Urol. 1982;138:77–82.
14.
Donohue J, Zachary J, Maynard S. Distribution of nodal metastases in non-seminomatous testicular cancer. J Urol. 1982;128:315–20.PubMed
15.
Narayan P, Lange P, Fraley E. Ejaculation and fertility after extended retro-peritoneal lymph node dissection for testicular cancer. World J Urol. 1982;127:685.
16.
Jewett M, Kong Y, Goldberg J. Retroperitoneal lymphadenectomy for testicular tumor with preservation of ejaculation. J Urol. 1988;139:1220–4.PubMed
17.
Donohue JP, Thornhill JA, Foster RS. Retroperitoneal lymphadenectomy for clinical stage a testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993;149(2):237–43.PubMed
18.
Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clin North Am. 1991;18(3):561–73.PubMed
19.
Brydoy M, Fossa SD, Klepp O. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005;97:1580.CrossRefPubMed
20.
Lange PH, Narayan P, Fraley EE. Fertility issues following therapy for testicular cancer. Semin Ural. 1984;2(4):264–74.
21.
Sheinfeld J. Nonseminomatous germ cell tumors of the testis: current concepts and controversies. Urology. 1994;44(1):2–14.CrossRefPubMed
22.
Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol. 1982;127(4):685–8.PubMed
23.
Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol. 1990;144(5):1160–3.PubMed
24.
Fossa SD, Klepp O, Ous S. Unilateral retroperitoneal lymph node dissection in patients with nonseminomatous testicular tumor in clinical stage I. Eur Urol. 1984;10(1):17–23.PubMed
25.
Jewett MA, Kong YS, Goldberg SD. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol. 1988;139(6):1220–4.PubMed
26.
Donohue JP, Foster RS, Rowland RG. Nerve sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144(2 Pt 1):287–92.PubMed
27.
Murphy BR, Breeden ES, Donohue JP. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993;11:324.CrossRefPubMed
28.
Ong Teng A, Winkler Mathias H, Savage Philip M, Seckl Michael J, Christmas Timothy J. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. BJUI. 2008;2:198–202.CrossRef
29.
Wood DP Jr, Herr HW, Motzer RJ. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer. 1992;70:2354.CrossRefPubMed
30.
Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer. 1998;83:1002.CrossRefPubMed
31.
Choueiri TK, Stephenson AJ, Gilligan T, et al. Management of clinical stage I nonseminomatous germ cell testicular cancer. Urol Clin North Am. 2007;34(2):137–48 (abstract: viii).CrossRefPubMed
32.
Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol. 2009;181(2):627–32.CrossRefPubMed
33.
Chamie K, Kurzrock EA, Evans CP. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer. 2011;117(18):v4219–30.CrossRef
34.
Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol. 2004;22(3):225–33.CrossRefPubMed
35.
Stephenson Andrew J, Bosl George J, Motzer Robert J, Kattan Michael W, Stasi Jason, Bajorin Dean F, Sheinfeld Joel. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23(12):2781–8.CrossRefPubMed
36.
George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 2003;21(1):113–22.CrossRefPubMed
37.
de Bruin MJ, Oosterhof GO, Debruyne FM. Nerve-sparing retroperitoneal lymphadenectomy for low stage testicular cancer. Br J Urol. 1993;71(3):336–9.CrossRefPubMed
38.
Stephenson Andrew J, Bosl George J, Motzer Robert J, Bajorin Dean F, Stasi Jason P, Seinfeld Joel. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIa and IIb nonseminomatous germ cell testicular cancer. J Clin Oncol. 2007;25(35):5597–602.CrossRefPubMed
39.
Hartmann JT, Schmoll H-J, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumours. Ann Oncol. 1997;8(6):531–8.CrossRefPubMed
40.
Sheinfeld JB, Bartsch G, Bosl G. Surgery for testicular tumors. In: Wein AJ, editor. Campbell-walshurology. 9th ed. Philadelphia: Saunders Elsevier; 2007. p. 936–64.
41.
Logothetis CJ, Samuels ML, Trindade A. The growing teratoma syndrome. Cancer. 1982;50(8):1629–35.CrossRefPubMed
42.
Motzer RJ, Amsterdam A, Prieto V. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;159(1):133–8.CrossRefPubMed
43.
Baniel J, Foster RS, Gonin R. Late relapse of testicular cancer. J Clin Oncol. 1995;13(5):1170–6.CrossRefPubMed
44.
De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, et al. 2-18fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22(6):1034–9.CrossRefPubMed
45.
Steyerberg EW, Keizer HJ, Fossa SD. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic non seminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995;13(5):1177–87.CrossRefPubMed
46.
Ehrlich Y, Brames M, Beck S. Long-term followup of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a post-chemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol. 2010;28(4):531–6.CrossRefPubMed
47.
Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H. Fossa SD Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21(17):3310–7.CrossRefPubMed
48.
Bosl GJ, Motzer RJ. Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. JCO. 2010;28(4):519–21.CrossRef
49.
Weissbach L, Boedefeld EA, Horstmann-Dubral B. Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Final results of a prospective multicenter trial 1982–1987. Testicular Tumor Study Group. Eur Urol. 1990;17(2):97–106.PubMed
50.
Eggener SE, Carver BS, Sharp DS. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007;177(3):937–42.CrossRefPubMed
51.
Carver BS, Shayegan B, Eggener S. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007;25(28):4365–9.CrossRefPubMed
52.
53.
Carver B, Cronin A, Eggener S. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010;75(6):1431–5.CrossRefPubMedPubMedCentral
54.
Steiner H, Zangerl F, Sthr B. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol. 2008;180(4):1348–52.CrossRefPubMed
Metadata
Title
Retroperitoneal lymph node dissection: an update in testicular malignancies
Author
K. Yadav
Publication date
01-07-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1622-5

Other articles of this Issue 7/2017

Clinical and Translational Oncology 7/2017 Go to the issue

Research Article

Predictive factors for survival in neoadjuvant radiochemotherapy for advanced rectal cancer

Research Article

Topography of the sentinel node according to the affected lobe in lung cancer

Research Article

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis

Review Article

Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential

Research Article

Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies

Research Article

Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits